Rabbit Recombinant Monoclonal TRIB3 antibody. Suitable for IP, WB and reacts with Human samples. Cited in 18 publications.
pH: 7.2 - 7.4
Preservative: 0.05% Sodium azide
Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 0.1% BSA
ICC/IF | IP | Flow Cyt | WB | IHC-P | |
---|---|---|---|---|---|
Human | Not recommended | Tested | Not recommended | Tested | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/10 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/5000 - 1/20000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Select an associated product type
Inactive protein kinase which acts as a regulator of the integrated stress response (ISR), a process for adaptation to various stress (PubMed:15775988, PubMed:15781252). Inhibits the transcriptional activity of DDIT3/CHOP and is involved in DDIT3/CHOP-dependent cell death during ER stress (PubMed:15775988, PubMed:15781252). May play a role in programmed neuronal cell death but does not appear to affect non-neuronal cells (PubMed:15775988, PubMed:15781252). Acts as a negative feedback regulator of the ATF4-dependent transcription during the ISR: while TRIB3 expression is promoted by ATF4, TRIB3 protein interacts with ATF4 and inhibits ATF4 transcription activity (By similarity). Disrupts insulin signaling by binding directly to Akt kinases and blocking their activation (By similarity). May bind directly to and mask the 'Thr-308' phosphorylation site in AKT1 (By similarity). Interacts with the NF-kappa-B transactivator p65 RELA and inhibits its phosphorylation and thus its transcriptional activation activity (PubMed:12736262). Interacts with MAPK kinases and regulates activation of MAP kinases (PubMed:15299019). Can inhibit APOBEC3A editing of nuclear DNA (PubMed:22977230).
C20orf97, NIPK, SKIP3, TRB3, TRIB3, Tribbles homolog 3, TRB-3, Neuronal cell death-inducible putative kinase, SINK, p65-interacting inhibitor of NF-kappa-B
Rabbit Recombinant Monoclonal TRIB3 antibody. Suitable for IP, WB and reacts with Human samples. Cited in 18 publications.
pH: 7.2 - 7.4
Preservative: 0.05% Sodium azide
Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 0.1% BSA
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
TRIB3 also known as TRB3 or NIPK is a pseudokinase with a molecular mass of approximately 42 kDa. This protein does not possess catalytic activity. It functions largely through interactions with other proteins. TRIB3 is expressed in various tissues with high levels in the liver kidney and brain. The regulatory functions of TRIB3 involve modulating cellular processes such as stress response and apoptosis by interacting with signaling proteins.
The modulation of metabolic pathways and stress responses involves TRIB3 acting in several mechanisms. While TRIB3 itself is not part of a complex it exerts its effects by binding to and inhibiting the activity of other proteins notably AKT1 and several transcription factors. This modulation influences glucose metabolism and cellular response to unfolded protein stress indicating TRIB3's role as a significant regulator of cellular homeostasis.
The influence of TRIB3 on insulin signaling and the unfolded protein response is significant. Within the insulin signaling pathway TRIB3 interacts with AKT1 a central protein that regulates glucose uptake and cell survival. This interaction inhibits AKT1's activity impacting glucose metabolism. In the unfolded protein response pathway TRIB3 impacts stress response regulation through interactions that modulate transcriptional activity further highlighting its regulatory roles.
Alterations in TRIB3 expression and activity relate to conditions such as type 2 diabetes and cancer. In type 2 diabetes increased TRIB3 levels impair insulin signaling via AKT1 inhibition contributing to insulin resistance. In cancer the dysregulation of TRIB3 can promote survival pathways circumventing apoptosis and aiding in tumor progression. The involvement of TRIB3 in these diseases highlights its potential impact in therapeutic targeting.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
TRIB3 was immunoprecipitated from 0.35 mg 293T (Human embryonic kidney epithelial cell) whole cell lysate 10 μg with 75846 at 1/50 dilution (2μg). VeriBlot for IP Detection Reagent (HRP)(VeriBlot for IP Detection Reagent (HRP) ab131366) was used at 1/5000 dilution.
Lane 1: 293T (Human embryonic kidney epithelial cell) whole cell lysate 10 μg
Lane 2: ab75846 IP in 293T whole cell lysate
Lane 3: Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) instead of ab75846 in 293T whole cell lysate
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
All lanes: Immunoprecipitation - Anti-TRIB3 antibody [EPR3151Y] (ab75846)
Predicted band size: 40 kDa
Observed band size: 40 kDa
All lanes: Western blot - Anti-TRIB3 antibody [EPR3151Y] (ab75846) at 1/10000 dilution
Lane 1: 293T cell lysates, treated with Ionomycin and TPA at 10 µg
Lane 2: 293T cell lysates, untreated at 10 µg
All lanes: HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 40 kDa
Observed band size: 40 kDa
ab75846 was shown to react with TRIB3 in wild-type HCT 116 cells in western blot with loss of signal observed in TRIB3 knockout cell line Human TRIB3 knockout HCT116 cell line ab273718 (TRIB3 knockout cell lysate Human TRIB3 knockout HCT116 cell lysate ab275249). Wild-type and TRIB3 knockout HCT 116 cell lysates were subjected to SDS-PAGE. Membranes were blocked in 3% milk in TBS-T (0.1% Tween®) before incubation with ab75846 and Anti-GAPDH antibody [6C5] - Loading Control ab8245 (Mouse anti-GAPDH antibody [6C5]) overnight at 4°C at a 1 in 10000 dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-TRIB3 antibody [EPR3151Y] (ab75846) at 1/10000 dilution
Lane 1: Wild-type HCT116 cell lysate at 20 µg
Lane 2: TRIB3 knockout HCT116 cell lysate at 20 µg
Lane 2: Western blot - Human TRIB3 knockout HCT116 cell line (Human TRIB3 knockout HCT116 cell line ab273718)
Lane 3: Hap1 cell lysate at 20 µg
Lane 4: HeLa cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 40 kDa
Observed band size: 40 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com